|Bid||0.0250 x 0|
|Ask||0.0260 x 0|
|Day's range||0.0260 - 0.0270|
|52-week range||0.0150 - 0.0430|
|Beta (5Y monthly)||1.30|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||0.11|
Roby Zomer has been the CEO of MGC Pharmaceuticals Limited ( ASX:MXC ) since 2016, and this article will examine the...
Under the terms of this agreement, MGC Pharma will provide a comprehensive suite of pharmaceutical services to advance Allied’s pharmaceutical products into human clinical PHASE 1. The scope of MGC Pharma’s services will cover clinical research, IMP registration, manufacturing of lab volumes for the research project, drug stability testing, GMP manufacturing and regulatory assistance for obtaining an Investigational Medicinal Product (IMP) number that is needed in order to sell the pharmaceutical product. Allied has also conducted an extensive prior art review on its previously submitted provisional patents for products AC001 and AC002 and has decided to abandon these.
In addition to this, through the MGC sales and distribution agreement, Allied will be able to sell their products following the completion of the PHASE I clinical trial. MGC currently has cannabis-based pharmaceutical products for sale in Europe and has demonstrated a proven ability to commercialize cannabis based pharmaceutical products.